When non-small cell lung cancer (NSCLC) spreads beyond the lungs, it often metastasizes to the bones. Estimates suggest 20 to 30 percent of people with NSCLC have bone metastases at the time of ...
The second most common cancer among men is prostate cancer, affecting 1 in 8 men. Prostate cancer is treatable, in most cases, when the cancer remains localized to the prostate gland. But if the ...
In a new study led by Johns Hopkins Medicine, the drug RK-33 has demonstrated promise in treating breast cancer that has spread to the bone (breast cancer bone metastasis). RK-33 was previously shown ...
Rice University researchers in the lab of chemist Han Xiao have identified a promising new immunological pathway to treat stubborn bone tumors, one of most prevalent forms of metastases in breast ...
Case study demonstrated resolution of lytic lesions, significant reduction in pain and prevention of fracture. ZetaMet™ is a first-of-its kind molecular pathway designed to suspend cancer, inhibit ...
Flash ultra-high dose rate therapy enabled by Varian proton and planning technologies Collaboration between Varian and leading institutions drives progress toward next-generation cancer treatments ...
In this exclusive MedPage Today video, Specht is joined via Zoom by study co-lead, Heather Jacene, MD, of Brigham and Women's ...
Zoledronic acid is a potent, new-generation bisphosphonate indicated for the treatment of documented bone metastasis in patients with solid tumors and bone lesions associated with multiple myeloma.
Laryngeal cancer may spread to cartilage, soft tissues, or lymph nodes in the neck area and to more distant sites, such as the lungs, liver, or bones. Treatment may depend on how far it has spread.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback